Literature DB >> 11986343

Thromboxane synthase immunohistochemistry in inflammatory bowel disease.

E Carty1, C Nickols, R M Feakins, D S Rampton.   

Abstract

BACKGROUND: Thromboxanes are produced in excess in inflammatory bowel disease. Preliminary reports suggest that ridogrel, a thromboxane synthase inhibitor, is anti-inflammatory and may have therapeutic benefits in patients with ulcerative colitis. AIMS: To investigate the immunohistochemical expression of thromboxane synthase in the colorectal mucosa of patients with inflammatory bowel disease.
METHODS: Immunostaining of colonic biopsies from patients with inflammatory bowel disease (n = 13) and controls (n = 5) was performed using a monoclonal antibody to human thromboxane synthase. The extent of staining in cells of the lamina propria was compared in patient and control groups, and was assessed in relation to disease activity scored macroscopically and histologically.
RESULTS: The percentage of cells in the lamina propria staining for thromboxane synthase was higher in patients with active inflammatory bowel disease than in those with inactive disease or in controls (p = 0.02 and p = 0.002, respectively). There was a direct correlation between disease activity, measured endoscopically and histologically, and the percentage of lamina propria cells staining for thromboxane synthase (R = 0.71, p = 0.001 and R = 0.72, p = 0.001, respectively).
CONCLUSIONS: Increased thromboxane synthase expression in lamina propria cells occurs in active inflammatory bowel disease. It is possible that this results in increased thromboxane synthesis, which may in turn contribute to mucosal inflammation and intramucosal thrombogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11986343      PMCID: PMC1769644          DOI: 10.1136/jcp.55.5.367

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  38 in total

1.  Ridogrel, a dual thromboxane synthase inhibitor and receptor antagonist: anti-inflammatory profile in inflammatory bowel disease.

Authors:  E Carty; M Macey; S A McCartney; D S Rampton
Journal:  Aliment Pharmacol Ther       Date:  2000-06       Impact factor: 8.171

2.  Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides.

Authors:  P Needleman; S Moncada; S Bunting; J R Vane; M Hamberg; B Samuelsson
Journal:  Nature       Date:  1976-06-17       Impact factor: 49.962

3.  Endogenous formation of the prostaglandin endoperoxide metabolite, thromboxane B2, by brain tissue.

Authors:  L S Wolfe; K Rostworowski; J Marion
Journal:  Biochem Biophys Res Commun       Date:  1976-06-07       Impact factor: 3.575

4.  Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction.

Authors:  A J Wakefield; A M Sawyerr; A P Dhillon; R M Pittilo; P M Rowles; A A Lewis; R E Pounder
Journal:  Lancet       Date:  1989-11-04       Impact factor: 79.321

5.  Production and characterization of polyclonal and monoclonal antibodies against human thromboxane synthase.

Authors:  R Nüsing; M P Wernet; V Ullrich
Journal:  Blood       Date:  1990-07-01       Impact factor: 22.113

6.  Metabolism and action of the prostaglandin endoperoxide PGH2 in rat kidney.

Authors:  T V Zenser; C A Herman; R R Gorman; B B Davis
Journal:  Biochem Biophys Res Commun       Date:  1977-11-21       Impact factor: 3.575

7.  Participation of thromboxane and other eicosanoid synthesis in the course of experimental inflammatory colitis.

Authors:  J Vilaseca; A Salas; F Guarner; R Rodriguez; J R Malagelada
Journal:  Gastroenterology       Date:  1990-02       Impact factor: 22.682

8.  Diversion of prostaglandin endoperoxide metabolism by selective inhibition of thromboxane A2 biosynthesis in lung, spleen or platelets.

Authors:  F P Nijkamp; S Moncada; H L White; J R Vane
Journal:  Eur J Pharmacol       Date:  1977-07-15       Impact factor: 4.432

9.  In vivo profiles of eicosanoids in ulcerative colitis, Crohn's colitis, and Clostridium difficile colitis.

Authors:  K Lauritsen; L S Laursen; K Bukhave; J Rask-Madsen
Journal:  Gastroenterology       Date:  1988-07       Impact factor: 22.682

10.  Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides.

Authors:  M Hamberg; J Svensson; B Samuelsson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-08       Impact factor: 11.205

View more
  2 in total

1.  Thromboxane-prostanoid receptor expression and antagonism in dextran-sodium sulfate-induced colitis.

Authors:  Patsy R Carter; Robert M McElhatten; Songlin Zhang; William S Wright; Norman R Harris
Journal:  Inflamm Res       Date:  2010-08-08       Impact factor: 4.575

2.  Simultaneous Quantitation of Lipid Biomarkers for Inflammatory Bowel Disease Using LC-MS/MS.

Authors:  Yashpal S Chhonker; Shrey Kanvinde; Rizwan Ahmad; Amar B Singh; David Oupický; Daryl J Murry
Journal:  Metabolites       Date:  2021-02-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.